In conclusion, the conceptual advance we present here is that targeting the crosstalk MEK signaling pathway is a new anxiolytic target, and that anti-cancer MEKi have the potential to be repurposed as anxiolytics for cAMP-mediated anxiety. This evidence concerns the gene MAP2K7 and cancer.